Hypertension Therapy Articles & Analysis
8 news found
“Apart from diabetes and hypertension management, there are currently very limited treatment options to slow kidney disease progression in people with chronic kidney disease and type 1 diabetes,” said Janet McGill, Professor of Medicine in the Division of Endocrinology, Metabolism and Lipid Research at Washington University, and Co-chair of the study’s Executive ...
ByBayer AG
“The results from the MODERATO II study offer compelling preliminary evidence that BackBeat CNT may provide a safe and effective therapy for ISH, which is the most common form of hypertension in older patients and one that is difficult to treat. The challenging nature of ISH often leads to the exclusion of these patients from hypertension ...
The data demonstrated that BackBeat Cardiac Neuromodulation Therapy™ (CNT™), a programmable and adjustable bioelectronic therapy delivered via an active implantable cardiac pulse generator, significantly reduced 24-hour ambulatory systolic blood pressure (aSBP) in patients with persistent hypertension and a clinical indication for a ...
Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company focused on developing transformative therapeutic products for large unmet medical needs in procedure-based medicine, today announced that long-term follow-up data on hypertensive patients from the control group of the MODERATO II study who received crossover ...
” MODERATO II is a European prospective, multi-center, double-blind, randomized study of BackBeat CNT (n=26) vs. control (n=21) in patients with persistent hypertension (ASBP ≥130 mmHg and oSBP ≥ 140 mmHg) despite one or more anti-hypertensive medications and a pacemaker indication. ...
Location: Hall J, David InterContinental Hotel Title: Bioelectronic Hypertension Treatment Targeting Pacemaker Patients: Results of Moderato II randomized Study with BackBeat Cardiac Neuromodulation Therapy Date/Time: December 10, 2019 at 4:12 PM IST Session: Electrophysiology IV - Startup Companies Presenter: Daniel Burkhoff, M.D., Ph.D. Location: Hall I, David ...
“We are excited to have them both join our leadership team at such an important time when our organization is accelerating late-stage development of both of our flagship therapies.” “I am honored to join the Orchestra BioMed leadership team, which is comprised of experienced, talented individuals that share my passion for creating groundbreaking new ...
“This is a particularly challenging at-risk population with a very high rate of isolated systolic hypertension and persistently elevated blood pressure despite multi-drug therapy. ...